Single User License
INR 129000
Site License
INR 258000
Corporate User License
INR 387000

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Axillary Hyperhidrosis-Pipeline Review, H1 2017

Axillary Hyperhidrosis-Pipeline Review, H1 2017


  • Products Id :- GMDHC9174IDB
  • |
  • Pages: 53
  • |
  • April 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Axillary Hyperhidrosis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axillary Hyperhidrosis-Pipeline Review, H1 2017, provides an overview of the Axillary Hyperhidrosis (Dermatology) pipeline landscape.

Axillary hyperhidrosis also referred to as excessive underarm sweating. Excessive sweating in the affected area is caused by over activity of the nerves linked to the sweat glands. Specifically, acetylcholine, a chemical in the body that transmits nerve signals, is released from nerve endings and stimulates secretion of sweat. The condition most frequently develops in adolescence or young adulthood. Treatment includes anticholinergic drugs, surgery and antiperspirants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axillary Hyperhidrosis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axillary Hyperhidrosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 4 and 1 respectively.

Axillary Hyperhidrosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis (Dermatology).

The pipeline guide reviews pipeline therapeutics for Axillary Hyperhidrosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Axillary Hyperhidrosis (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Axillary Hyperhidrosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis (Dermatology)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Axillary Hyperhidrosis (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Axillary Hyperhidrosis (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Axillary Hyperhidrosis-Overview

Axillary Hyperhidrosis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Axillary Hyperhidrosis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Axillary Hyperhidrosis-Companies Involved in Therapeutics Development

Allergan Plc

Brickell Biotech Inc

Dermira Inc

Dr. August Wolff GmbH & Co KG Arzneimittle

GlaxoSmithKline Plc

TheraVida Inc

Axillary Hyperhidrosis-Drug Profiles

(oxybutynin chloride + pilocarpine hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

botulinum toxinA-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glycopyrrolate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glycopyrronium tosylate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sofpironium bromide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

umeclidinium bromide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Axillary Hyperhidrosis-Dormant Projects

Axillary Hyperhidrosis-Discontinued Products

Axillary Hyperhidrosis-Product Development Milestones

Featured News & Press Releases

Mar 21, 2017: Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting

Mar 17, 2017: Dermira to Present Data on Glycopyrronium Tosylate Clinical Program at Annual Maui Derm Meeting

Mar 03, 2017: Dermira Presents New Data in Primary Axillary Hyperhidrosis at American Academy of Dermatology 2017 Annual Meeting

Feb 27, 2017: TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis

Feb 27, 2017: Dermira Data from DRM04 Clinical Program to Be Presented at American Academy of Dermatology Annual Meeting

Oct 13, 2016: Dermira to Present Data from DRM04 Clinical Program at Fall Clinical Dermatology Conference

Oct 03, 2016: THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis

Oct 01, 2016: Dermira Presents Data from DRM04 Phase 3 Clinical Program in Late-Breaking News Session at European Academy of Dermatology and Venereology Congress

Sep 28, 2016: Dermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology Congress

Jun 01, 2016: Dermira Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Trials for DRM04 in Patients with Primary Axillary Hyperhidrosis

Mar 07, 2016: BBI-4000 (Sofpironium Bromide) Demonstrates Promising Potential as a Safe and Effective First-line Treatment for Excessive Underarm Sweating

Feb 29, 2016: Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis

Jan 07, 2016: Dermira Provides DRM04 Development Program Update

Dec 17, 2015: Brickell Biotech Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 in Patients with Hyperhidrosis

Aug 03, 2015: Dermira Doses First Patients in DRM04 Phase 3 Program in Axillary Hyperhidrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Axillary Hyperhidrosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Axillary Hyperhidrosis, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Axillary Hyperhidrosis-Pipeline by Allergan Plc, H1 2017

Axillary Hyperhidrosis-Pipeline by Brickell Biotech Inc, H1 2017

Axillary Hyperhidrosis-Pipeline by Dermira Inc, H1 2017

Axillary Hyperhidrosis-Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H1 2017

Axillary Hyperhidrosis-Pipeline by GlaxoSmithKline Plc, H1 2017

Axillary Hyperhidrosis-Pipeline by TheraVida Inc, H1 2017

Axillary Hyperhidrosis-Dormant Projects, H1 2017

Axillary Hyperhidrosis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Allergan Plc, Brickell Biotech Inc, Dermira Inc, Dr. August Wolff GmbH & Co KG Arzneimittle, GlaxoSmithKline Plc, TheraVida Inc


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com